The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by patients worldwide to treat a variety of diseases and serious medical conditions. PPTA member companies produce approximately 80% of the plasma protein therapies in the U.S. and 60% of those manufactured in Europe.
PPTA works globally to:
Patient Organizations and Industry Join Together to Celebrate Third Annual International Plasma Awareness Week +
Congresswoman Doris Matsui Recognizes International Plasma Awareness Week +
Annapolis, Md.— On October 8, the Honorable Doris O. Matsui (D-CA) entered into the Congressional Record her statement recognizing the third annual International Plasma Awareness Week (IPAW), to be celebrated October 11-17.Read More
PPTA Comments on the IQWiG Rapid Report on Haemophilia Therapies +
On October 11, 2012, the German Federal Ministry of Health (BMG) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess the treatment of haemophilia patients through the production of a Health Technology Assessment (HTA) Rapid Report.Read More
The Source, the international magazine of the plasma protein therapeutics industry is published quarterly. Read the current issue.